Biotechnology Companies in the News – November 2011
Published in Biolines November 2011
Editor’s Note: The home page of the BioNJ website provides an up-to-the-minute headline service where readers can access press releases issued by New Jersey-based biotechnology companies. Go to the “New Jersey Biotechnology Company News” section on the BioNJ home page to read the latest news. Companies wishing to appear in the Biolines Biotechnology Companies in the News section are encouraged to send their news releases to BioNJ via email.
November 10
Merck Executing on Strategy to Position Company for Long-Term Sustainable Growth
Merck Highlights Pipeline Progress and Showcases Novel Innovations at R&D and Business Briefing
November 9
LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference
Unigene Reports Third Quarter 2011 Financial Results
Unigene Announces Positive Top-Line Results Of Phase 2 Oral Pth Study For The Treatment Of Osteoporosis In Postmenopausal Women
BioReference Laboratories, Inc. to Speak at the Lazard Capital Markets 8th Annual Healthcare Conference
CircuLite® to Present at Lazard Capital Markets Healthcare Conference
Merck Launches NEXPLANON® (etonogestrel implant) 68 mg in the United States – A Long-Acting Reversible Hormonal Contraceptive Effective For Up to Three Years
November 8
BioNeutral Group Signs Definitive Agreements to Improve Balance Sheet by $6.8 Million and Lower Debt to Nearly Zero
Epratuzumab Phase IIB Data Demonstrated Sensitivity of BICLA, a Novel BILAG-Based Composite Endpoint
Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-1127
12-Week On-Treatment Results from Large Phase IIb Study (COMMAND-1) of Bristol-Myers Squibb’s NS5A Inhibitor Daclatasvir Support Anti-HCV Activity and Safety Profile Observed in Earlier Studies
Outstanding Interim Results of STENTYS International Clinical Study of 600 Heart Attack Patients
Antares Pharma Reports Third Quarter 2011 Financial and Operating Results
Flexible Stenting Solutions, Inc. Announces First Implant of the 200 mm FlexStent® Femoropopliteal Self Expanding Stent System
Oceana Therapeutics Announces Definitive Agreement to Be Acquired by Salix Pharmaceuticals
Phase IIIb Comparison of BARACLUDE® (entecavir) Monotherapy Versus BARACLUDE Plus Tenofovir Combination Shows No Statistical Difference Between Study Arms
Pharmasset to Present at Credit Suisse First Boston Healthcare Conference
First Research Results of Angiomax(R) (Bivalirudin) Versus Heparin in Transcatheter Aortic Valve Interventions Reported at TCT
Phase II Study Evaluating Apremilast as an Oral Treatment for Patients with Ankylosing Spondylitis Presented at ACR
November 7
NPS Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase 3 REPLACE Study of NPSP558 in Hypoparathyroidism
FDA Approves ERBITUX® (cetuximab) for First-Line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-Fluorouracil
All-Oral Treatment Regimen of Bristol-Myers Squibb’s Investigational NS5A and NS3 Inhibitors Achieved 90% Sustained Virologic Response (SVR12) in Phase II Study Sentinel Cohort of Genotype 1b Null Responders
PTC Therapeutics Receives Grand Challenges Explorations Funding
November 4
NPS Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
Pharmasset to Webcast an Investor Event from the AASLD Meeting
November 3
Columbia Laboratories Reports Third Quarter 2011 Financial Results
BioNeutral Group Appoints New Board of Directors and Expands Management Team
ASLAN Pharmaceuticals and Bristol-Myers Squibb Enter Innovative Partnership to License and Develop Investigational Oncology Compound
New Investigational Data on ORENCIA® (abatacept) to Be Presented at the American College of Rheumatology Annual Scientific Meeting
NPS Pharmaceuticals Reports Third Quarter 2011 Financial Results and Improves Cash Burn Guidance
Senesco Initiates Dosing in Phase 1b/2a Clinical Study of SNS01-T
Enzon Reports 3rd Quarter 2011 Results
Celgene Corporation to Present at the Credit Suisse 2011 Healthcare Conference
November 2
Celldex Reports Third Quarter 2011 Financial Results
The Medicines Company Announces Schedule of Events at Upcoming Transcatheter Cardiovascular Therapeutics (TCT) Conference
November 1
NovaDel Reports Financial Results for Third Quarter 2011
MedAvante Is One Of NJ’s Fastest Growing Companies
Amicus Therapeutics Announces Third Quarter 2011 Financial Results
Pharmasset Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977 for HCV
October 31
Phase 3 GATTEX(R) (teduglutide) Data Highlight Potential New Treatment for Adults with Short Bowel Syndrome
NPS Pharmaceuticals to Host Conference Call to Discuss Data Reported at American College of Gastroenterology Annual Scientific Meeting
Celldex Therapeutics Announces Orphan Drug Designation in the European Union for Rindopepimut, a Novel EGFRvIII Vaccine for Glioblastoma
Merck Announces Dates for R&D and Business Briefing and Fourth-Quarter 2011 Sales and Earnings Report
October 28
Merck Announces Third Quarter 2011 Financial Results
Advaxis Receives Additional Financing
For Immediate Release to US Investors: The Medicines Company and Daiichi Sankyo Announce Angiox(R) (Bivalirudin) Co-Promotion for Germany
October 27
Bristol-Myers Squibb Delivers Strong Third Quarter with Important Clinical Data, Solid Operating Results and Continued Focus on Business Development
Columbia Laboratories to Discuss Third Quarter 2011 Financial Results on November 3, 2011, Conference Call
Celgene Reports Record Third Quarter 2011 Operating and Financial Results
SwabCap Is Focus of NACHRI Pediatric Conference Award
GenPath Women’s Health in Collaboration with GeneDX to Launch Breakthrough in Genetic Screening for Family Planning
NPS Pharmaceuticals to Report Third Quarter 2011 Financial Results
October 26
Bristol-Myers Squibb and Gilead Sciences Announce Licensing Agreement for Development and Commercialization of New Fixed-Dose Combination Pill for People Living with HIV
GE Healthcare Presents at TEDMED Conference on Importance of Molecular Diagnostics in Personalized Treatment Paradigm
Senesco Technologies Provides Corporate Update
U.S. Food and Drug Administration Extends Action Date for Dapagliflozin by Three Months
New Approaches from Regional Researchers Recognized at Biotech 2011 Innovation Corridor
New England Journal of Medicine Publishes Additional Efficacy and Safety Data for GARDASIL® in Males
The Medicines Company Reports Third Quarter 2011 Results
October 25
Pop Test Cortisol Acquires Chemotherapy Sensitizer Org34517 from Merck & Co.
Paragon Co-Chairs Second CBI Conference on Electronic Trial Master File Implementation
CDC Advisory Committee on Immunization Practices Votes for Expanded Use of GARDASIL® in Boys and Young Men
University of Michigan Oncologist Receives Breast Cancer Research Foundation Grant for Work with Tumor Markers
BioReference’s Genetic-Testing Business Has New Tool for Detecting Rare Diseases
Celldex Therapeutics to Participate on Business Development Panel at BIO-Europe® 2011 in Duesseldorf, Germany
October 24
ViroStatics CEO, Dr. Franco Lori, to Speak at the International Track During Pennsylvania Biotech 2011
Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing At Commercial Scale
October 21
Data from Phase 2 Clinical Studies of Telotristat Etiprate in Patients with Carcinoid Syndrome to Be Presented at North American Neuroendocrine Tumor Society Meeting
October 20
Cardiac Device Infections Cost Money and Lives
Unigene Completes All Patient Dosing in Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women
Unigene to Present at the 10th Annual BIO Investor Forum on October 25, 2011
Senesco Technologies to Present at BIO Investor Forum Conference
October 19
NCPDP and SAFE-BioPharma to Collaborate on Life Science Standards
Columbia Laboratories Recognized on the Deloitte Technology Fast 500
Amicus Therapeutics Announces Close of Patient Recruitment in First Phase 3 Study of Amigal(TM) for Fabry Disease
Bristol-Myers Squibb Announces Changes in Senior Management Team
Bristol-Myers Squibb Foundation Awards $2.12 Million in Grants to Help Returning Soldiers Heal Emotional Wounds of War
October 18
Dr. Roberto Romero, NIH Principal Investigator of PREGNANT Study, Co-Sponsored by Columbia Laboratories, Honored with John Dingell Hero for Babies Award by March of Dimes
Advaxis Announces Notice of Allowance of US Patent for ADXS-HPV Immunotherapy
Canyon Pharmaceuticals Honored with Frost & Sullivan Award for Product Differentiation Excellence in Parenteral Anticoagulants
Sentrx Enhances Performance Management Metrics
October 17
Advaxis to Present at the 2011 10th Annual BIO Investor Forum on October 25th
Enzon Announces Management Change, Forms Special Committee of the Board
October 15
The Medicines Company’s MDCO-2010 Meets Clinical Trial Objectives in Patients Undergoing Open-Heart Surgery
October 14
Sentrx Announces Resignation of Charles T. Saldarini as CEO
